SWOBY (Swedish Orphan Biovitrum AB) Beneish M-Score: -2.62 (As of Jun. 24, 2026)


SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $23.18
GF Value $17.17
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Beneish M-Score?

Swedish Orphan Biovitrum AB SWOBY 67 Beneish M-Score is -2.62 as of Jun. 24, 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 911 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 61.03% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.62 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Beneish M-Score or its related term are showing as below:

SWOBY' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.39   Max: -1.57
Current: -2.62

During the past 13 years, the highest Beneish M-Score of Swedish Orphan Biovitrum AB was -1.57. The lowest was -3.00. And the median was -2.39.


Swedish Orphan Biovitrum AB Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Beneish M-Score Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.77 -2.25 -2.51 -2.55 -3.00

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.58 -2.96 -3.00 -2.62

SWOBY vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Beneish M-Score falls into.


SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Swedish Orphan Biovitrum AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1987+0.528 * 0.9989+0.404 * 0.9768+0.892 * 1.2316+0.115 * 0.8102
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9222+4.679 * -0.079134-0.327 * 1.1632
=-2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $996 Mil.
Revenue was 770.94 + 841.556 + 829.644 + 646.719 = $3,089 Mil.
Gross Profit was 583.544 + 666.918 + 657.441 + 497.371 = $2,405 Mil.
Total Current Assets was $1,642 Mil.
Total Assets was $8,721 Mil.
Property, Plant and Equipment(Net PPE) was $175 Mil.
Depreciation, Depletion and Amortization(DDA) was $1,060 Mil.
Selling, General, & Admin. Expense(SGA) was $920 Mil.
Total Current Liabilities was $2,329 Mil.
Long-Term Debt & Capital Lease Obligation was $849 Mil.
Net Income was 141.459 + 200.247 + -308.876 + 66.609 = $99 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 120.852 + 320.762 + 196.315 + 151.652 = $790 Mil.
Total Receivables was $674 Mil.
Revenue was 638.027 + 676.923 + 673.966 + 519.024 = $2,508 Mil.
Gross Profit was 481.308 + 531.27 + 543.846 + 394.393 = $1,951 Mil.
Total Current Assets was $1,156 Mil.
Total Assets was $6,920 Mil.
Property, Plant and Equipment(Net PPE) was $156 Mil.
Depreciation, Depletion and Amortization(DDA) was $355 Mil.
Selling, General, & Admin. Expense(SGA) was $810 Mil.
Total Current Liabilities was $1,180 Mil.
Long-Term Debt & Capital Lease Obligation was $988 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(995.685 / 3088.859) / (674.443 / 2507.94)
=0.322347 / 0.268923
=1.1987

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1950.817 / 2507.94) / (2405.274 / 3088.859)
=0.777856 / 0.778693
=0.9989

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1641.695 + 175.267) / 8721.182) / (1 - (1156.146 + 155.633) / 6920.101)
=0.791661 / 0.810439
=0.9768

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3088.859 / 2507.94
=1.2316

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(354.996 / (354.996 + 155.633)) / (1059.967 / (1059.967 + 175.267))
=0.695213 / 0.85811
=0.8102

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(919.94 / 3088.859) / (809.963 / 2507.94)
=0.297825 / 0.322959
=0.9222

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((849.182 + 2329.348) / 8721.182) / ((987.782 + 1180.424) / 6920.101)
=0.364461 / 0.31332
=1.1632

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(99.439 - 0 - 789.581) / 8721.182
=-0.079134

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Swedish Orphan Biovitrum AB has a M-score of -2.53 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.62 mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Beneish M-Score of -2.62 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Swedish Orphan Biovitrum AB and its competitors. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #355 out of 911 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Swedish Orphan Biovitrum AB's Beneish M-Score too high?
Swedish Orphan Biovitrum AB's current Beneish M-Score is -2.62. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #355 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #355 out of 911 companies for Beneish M-Score. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Beneish M-Score is -2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Beneish M-Score is -2.62. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Beneish M-Score is -2.62 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for SWOBY:

  • Beneish M-Score: -2.62
  • GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.18
Price
$17.17
GF Value